Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a significant stock price increase, attributed to a new distribution agreement with PT Ferron Par Pharmaceuticals for its core product, a atropine eye drop aimed at slowing myopia progression in children and adolescents [1] Company Summary - Zhaoke Ophthalmology has signed a distribution and supply agreement with PT Ferron Par Pharmaceuticals, granting exclusive rights for importing, promoting, distributing, marketing, and selling its atropine eye drop product in Indonesia [1] - The company will receive an upfront payment and may earn additional milestone payments based on certain achievements related to the product [1] - Earlier this year, Zhaoke Ophthalmology's applications for a simplified new drug for 0.01% and 0.02% concentrations of the atropine eye drop have been accepted by the National Medical Products Administration of China and are currently under review [1] Market Reaction - Following the announcement, Zhaoke Ophthalmology's stock price increased by over 7%, with a current price of 4.27 HKD and a trading volume of 10.8763 million HKD [1]
港股异动 | 兆科眼科-B(06622)再涨超7% 公司与PT Ferron达成战略合作 推动核心产品在印尼商业化